摘要
目的:了解2009～2010年我院口服降糖药的使用状况及发展趋势,为口服降糖药的合理用药提供参考。方法:采用金额排序法和DDD分析法,对我院口服降糖药的用药金额、用药频度(DDDs)、日均费用(DDDc)等进行统计与分析。结果:2009～2010年口服降糖药的品种、数量及销售金额等逐年增长;2010年用药金额前3位为阿卡波糖、瑞格列奈、格列齐特(2009年前二者无变化,第3位为格列美脲);用药频度前3位保持为二甲双胍、格列美脲、阿卡波糖;日均费用前3位为罗格列酮、阿卡波糖、瑞格列奈。结论:我院临床口服降糖药应用中,糖苷酶抑制剂阿卡波糖、磺脲类药物的格列齐特和双胍类药物的二甲双胍均为因其疗效好、不良反应较少等居主导地位,为一线降糖药物新型药物,有较大的发展空间。我院口服降糖药的总体应用较为合理。
Objective： To evaluate the usage of oral hypoglycemic drugs in our hospital in order to provide reference for rational use of drugs in clinic. Methods： DDDs, sales volume and daily expenses of oral hypoglycemic agents in our hospital from 2009 to 2010 were analyzed with the method of amount of money rank and DDD analysis. Results： The variety, quantity and amount of oral hypoglycemic drugs increased year by year. Acarbose, Repaglinide and Gliclazide were the top 3 in 2010, which differed a little with those in 2009 （the third was Glimepiride）; DDDs of Metformin, Glimepiride and Acarbose were the top 3; DDDc of Rosiglitazone, Acarbose and Repaglinide were the top 3. Conclusion： In our hospital, Acarbose of Glyeosidase inhibitors, Glielazide of Sulfonylureas and Mefformin of Biguanide are the most common because their good effects and few adverse reactions. The usage of oral hypoglycemic agents in our hospital is rational.
出处
《中国医药导报》
CAS
2011年第32期151-152,共2页
China Medical Herald
